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Abstract
Purpose of review—To describe the pathology, impact of comorbidities, functional limitations, 
symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in 
older adults.
Recent findings—AML is a rare aggressive hematologic disease that occurs most often in older 
adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and 
patient characteristics such as comorbidities and functional limitations. Patient characteristics may 
influence treatment decisions, as well as impact symptoms, functional ability, health-related 
outcomes and (QOL).
Summary—As the population continues to age, the number of people diagnosed with AML is 
expected to increase. Better management of comorbidities is imperative to improving QOL and 
other treatment related outcomes. Prospective, longitudinal and multi-site studies are warranted to 
further understand the interaction between these characteristics on symptoms, outcomes and QOL.
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Introduction
Acute myeloid leukemia (AML) is a rare aggressive hematologic disease that afflicts 3–4 
persons per 100,000 individuals annually (1, 2). In the United States, estimates predict 
21,830 new cases of AML with approximately 10,590 AML related deaths in 2017 (3). The 
risk for AML increases with age, and recent Surveillance Epidemiology and End Results 
Data (SEER) indicates that over 70% of new AML cases are diagnosed in adults ≥ 55 years 
of age with the median age of diagnosis being 67 years of age (1, 4). The prognosis for older 
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patients diagnosed with AML is notably worse due to poor cytogenetic characteristics, 
genetic mutations that confer resistance to chemotherapy and patient clinical characteristics 
such as comorbidities and physical function (5, 6).
AML is a disease of the hematopoietic system in the bone marrow resulting in a 
transformation of leukocytes and leukocyte precursors into malignant cells (7). A large 
number of these immature, abnormal cells proliferate rapidly and accumulate in the bone 
marrow suppressing the hematopoietic system (7). The etiology of leukemia is unknown, 
environmental exposure, genetic characteristics and the process of aging can cause a gradual 
deterioration of the immune system (immunosenescence), increasing the risk for the 
development of AML (8). The normal aging process creates a milieu of persistent low-grade 
inflammation, known as “inflammaging” which is characterized by increased levels of 
circulating pro-inflammatory cytokines, (IL-1, IL-6 and TNF-α) (9, 10). These pro-
inflammatory cytokines facilitate cellular aberrations that decrease the ability of the immune 
system to conduct its usual surveillance and immune-editing activities when exposed to 
foreign pathogens and/or self-antigens (11, 12). Continuous exposure of cells to systemic 
inflammation throughout the aging process is a contributing factor in the increased 
vulnerability to cancer, infectious diseases, diabetes, heart disease, neurodegeneration and 
other age related chronic comorbid diseases (9, 10, 13). Additionally, environmental 
exposures to benzene and ionizing radiation have also been associated with an increased risk 
for leukemias (14).
The treatment regimen for AML is aggressive and associated with high acuity, fluctuating 
symptoms and a high financial cost. Standard regimens involve cycles of induction 
chemotherapy, consolidation chemotherapy, and when appropriate, allogeneic hematopoietic 
cell transplantation; with the goal of achieving complete remission with possible cure of the 
disease (15, 16). Older individuals, often do not tolerate aggressive therapies and are more 
likely to experience poor health outcomes such as longer neutropenia (low white blood cell 
count), increased rates of infection and longer hospital length of stay (17–19). Additionally, 
older patients with AML are less likely to achieve complete remission and remain relapse 
free compared to their younger counterparts (15, 20). The disparity in these outcomes among 
younger versus older patients (< 60 years of age vs ≥ 60 years of age) may be due to 
differences in cytogenetics, subsequent resistance to chemotherapy, treatment-related 
toxicity, immune suppression resulting in increased vulnerability to bacterial and fungal 
infections, decreased physical functional reserve, organ dysfunction and/or comorbidities (6, 
8, 20–24). Changes to physical and functional abilities may be exacerbated due to the 
treatment regimens for AML. Side effects from treatment, in addition to managing 
comorbidities, can affect health outcomes and overall quality of life (QOL). Managing 
comorbidities, improving health outcomes, and maintaining QOL for older patients with 
AML is important to consider during and after treatment. Little is known regarding the 
impact of comorbidities, physical function, and symptoms on the QOL and health outcomes 
of older patients receiving treatment for AML. Therefore, the purpose of this short review is 
to describe comorbidity, symptoms and QOL experienced by older adults with AML. 
Specifically, this review will focus on the comorbidities and measures used in AML, and 
QOL related to treatment in older adults with AML.
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Comorbidities and AML
Advanced age is often accompanied by frailty and comorbidities, which have an important 
impact on the tolerance that older patients diagnosed with AML may have to intensive 
treatment modalities (1). Treatment choice also depends on a variety of factors, including 
age, performance status, and comorbidities (25). Studies have shown older patients with 
AML can benefit from standard therapy regimens; however, there is often reluctance among 
clinicians especially in the presence of comorbidities due to the difficulty of predicting risk/
benefits of available therapies (11, 17, 26). Concern of treatment toxicity and/or mortality 
may influence clinicians’ decisions regarding treatment regimen and/or reduction in the 
intensity of treatment (21).
Researchers have demonstrated that comorbidities are an independent predictor of all-cause 
mortality in patients with AML (24, 27, 28). In one prospective observational study 
examining change in QOL scores and their association with therapy and survival in older 
adults with AML, researchers found at least one comorbid disease was present in 70% 
patients with AML in the palliative treatment group and 48% of those in the intensive 
treatment group (15). Several important prognostic factors for AML such as age, gender, and 
socioeconomic status are associated with comorbidity, and these factors may potentially 
explain the adverse effect of comorbidity on prognosis (29).
There are also health-related outcomes to consider when examining treatment related to 
older adults with AML. For example, studies of older adults with AML have shown a 
relationship between increased comorbidity burden and worse outcomes including toxicity, 
hospital readmission rates, 30-day mortality, and worse overall survival (24, 28, 30). 
Although the initial therapy for AML has been standardized and forms the backbone of 
clinical trials, some patients do not receive conventional therapy at diagnosis due to existing 
or potential comorbidities which may also impact prognosis and health outcomes (8).
Diabetes is a common comorbidity that occurs with aging (31). Older patients with 
comorbid diabetes and cancer have been found to have poorer health outcomes than cancer 
patients without diabetes (32–34). In older patients with AML, diabetes was found to be 
adversely associated with 30-day survival rates (30). Hyperglycemia defined as a blood 
glucose ≥ 140 mg/dL (35), has been noted to occur in up to 38% of hospitalized patients 
including those with a diagnosis of diabetes and those without diabetes (36). The onset of 
hyperglycemia can occur in those with and without a diagnosis of diabetes, a recent review 
noted 11% of inpatients with no prior history of diabetes experienced hyperglycemia 
(37).Diabetes and/or hyperglycemia are often exacerbated by the administration of 
glucocorticosteroids as part of the chemotherapy treatment regimen (38). Standard screening 
of patients with AML prior to the onset of treatment could be beneficial in predicting and 
managing those patients who may be a higher risk for exacerbation of their diabetes and/or 
the development of hyperglycemia. Independent of a diagnosis of diabetes, hyperglycemia 
has been shown to impact the health outcomes of patients with cancer (39, 40). For example, 
patients with AML who experienced hyperglycemia were found to have a greater risk for 
infection, (19, 41), sepsis, (42), longer hospital length of stay (18) and mortality. However, 
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inconsistencies in definitions and measurement practices between studies make it difficult to 
interpret the full impact of hyperglycemia on health outcomes(43).
Comorbidity Measures in AML
There are risk assessments that help to measure the potential impact of comorbidities on 
health outcomes related to survival and mortality rates. The Charlson Comorbidity Index 
(CCI) and Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) are 
frequently used to measure comorbidities (44). The CCI assigns point values for certain 
comorbidities, some of which are stratified for severity (44). The original CCI has been 
revised slightly for use in older adults with AML (44). A single-center retrospective study 
showed that patients with a CCI score >1 had a significantly lower chance of attaining a 
complete remission compared to those with a score of 0 or 1 (35 versus 63%, respectively) 
(44). The group with higher CCI scores also showed a trend toward higher 8-week mortality 
and lower 2-year survival (44). The HCT-CI was developed to improve the sensitivity of the 
CCI in the stem cell transplant setting, but has been evaluated as a tool to predict outcomes 
with intensive induction chemotherapy for AML as well (44). Overall, the importance of 
comorbidities has not been well established in older patients with AML. However, it has 
been shown that AML cancer survivors who have comorbid disease(s) experience lower 
levels of QOL, (45) have poorer physical function, and less able to self-manage their disease 
(46). The assessment of comorbidities prior to treatment is critically important to better 
facilitate choice of treatment options. More research is necessary to determine which 
comorbid risk assessment tool best identifies the comorbidity or cluster of comorbid 
conditions that exert the most influence on the health outcomes of older patients with AML. 
The impact of comorbidities on the severity of symptoms experienced by older patients with 
AML is unknown. Future research should examine the interaction between a diagnosis of 
AML, comorbidities, and normal aging health related issues on symptom severity.
Symptom and Physical Function Changes for Older Adults with AML
Fatigue has been found to be the most common, distressing symptom that has been reported 
by more than 90% of adults with AML during treatment (47, 48). Fatigue significantly 
impacts QOL, leading to restrictions in activities of daily living (ADLs), and is particularly 
severe during chemotherapy (48, 49). Hospitalization can be detrimental to adults with AML 
as it can reduce functional abilities, endurance, and overall health (50, 51). Functional 
decline is a major concern for older adults with AML. Irrespective of previous physical 
ability or frailty, older adults who are hospitalized are at an increased risk for disability (52). 
Furthermore, hospital length of stays can be up to 35% longer for those who require 
assistance from basic activities, such as dressing and bathing, to more complex activities like 
pain management (53). A central focus of cancer rehabilitation is improvement of body 
function, fatigue and overall QOL (54–56). Therefore, exercise has been introduced to 
various cancer populations during and post-treatment due to its positive impact on physical 
health, fatigue, symptoms and functioning.
The American College of Sports Medicine published exercise guidelines for cancer 
survivors which recommend that survivors of cancer achieve 150 minutes of moderate to 
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vigorous intensity aerobic activity weekly (57). There are several physical (symptom 
reduction) and psychological benefits (decreased anxiety and depressive symptoms) 
associated with exercise for survivors (57–59). Before a patient starts to exercise, a 
functional assessment is recommended to be completed by professionals such as 
occupational therapists, physical therapists, recreational therapists, exercise physiologists, or 
a registered nurse. Common functional measures used in practice and research are Eastern 
Cooperative Oncology Group (ECOG), clinician or patient rated Karnofsky Performance 
Scale (KPS) that quantify and capture how well an individual is able to engage in daily 
activities while having AML and determine how well the individual will be able to tolerate. 
The geriatric assessment is a more comprehensive approach to assess function as ECOG and 
KPS are crude assessments of function (Table 1).
Five exercise studies conducted in patients with AML have shown beneficial effects on 
cardiorespiratory fitness, muscle strength and functional mobility (47, 60–63). These 
benefits are critical in ensuring that the patient remains active and functional during their 
hospitalization and after hospital discharge. Most of these studies involved small sample 
sizes (10–35), and statistically significant improvements in symptoms such as fatigue, 
anxiety, depression or QOL were found (5, 47, 60, 64)(Table 2).
Quality of Life in AML
Recognized as one of the most important patient-reported outcomes, QOL includes physical, 
psychological, emotional,, spiritual, and sexual function domains (7,51,(65). An AML 
diagnosis may significantly impact QOL of affected individuals, which is underscored by the 
fact that 97% of patients older than 60 years with AML report that QOL is more important 
than length of life (65). Given the short life expectancy of many older patients with AML 
and the low likelihood of cure, patients may wish to consider the impact of cancer therapy 
on their QOL (66). Therefore, maximizing QOL should be an important goal when treating 
this population and eliciting patient preferences and goals of treatment are necessary to 
formulate a personalized treatment plan. The optimal target should be to cure the disease 
without compromising on patient’s QOL, as well as maintaining general functioning and 
cognition in the long term (1).
The psychosocial burden of disease as a psychosocial construct in terms of the in older 
patients with AML is huge for the patient, especially during active treatment (1). In the 
context of this paper, the psychological burden of disease refers to the emotional stress of 
living with a diagnosis of cancer and its treatment, fear of recurrence, and the distress 
imposed by living with the day-to-day physical problems that can create new or worsen 
preexisting psychological distress for people living with cancer, their families, and other 
informal caregivers (67).
Cancer is a stressful time for both patients and family members who are often expected to 
deal with cancer-related symptoms (68). Spirituality, a fundamental element of human 
experience that encompasses the individual’s search for meaning and purpose in life, could 
be an important factor that helps a person in coping with the disease process (69). Quality of 
life may be influenced by an individual’s previous health status prior to the cancer diagnosis. 
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Evidence suggests that for “fit” patients, older age is associated with QOL and physical 
function similar to those of younger patients during and after intensive chemotherapy (20). 
Furthermore, coping strategies are an integral role in survivorship, and interventions to 
enhance effective coping are instrumental to improve adaptation and leukemia survivors’ 
QOL (70).
Since intensive chemotherapy is known to be rarely beneficial for frail older adults or those 
with poor-risk disease, AML may be better-managed using palliative care approaches that 
focus on QOL and symptom management (15, 44). Despite the poor prognosis associated 
with AML, palliative care and hospice services are rarely used (66). This population could 
benefit from early referral to palliative care concurrently while pursuing induction 
chemotherapy (66). For example, patients who are deemed too frail for myelosuppressive 
therapy because of multiple comorbidities, may benefit from low-intensity therapies (such as 
low-dose cytarabine) in conjunction with palliative care (71, 72). Early integration of 
palliative care improves QOL and symptom burden and decreases health service utilization 
in patients with solid malignancies. Employing a similar strategy in older adults with AML 
may prove valuable in improving QOL and health care delivery.(66). However, the absence 
of a clear transition between the curative and palliative phases of disease for older patients 
with AML may hamper the receipt of hospice services (66). Research comparing health care 
utilization and end-of-life care in older patients with AML found that only a minority of 
patients dying of AML utilized Hospice services. The frequent need for blood product 
support, which many hospice organizations do not permit because of financial constraints, 
likely contribute to lower rates of hospice referrals (66). More research is needed to assess 
the availability and impact of palliative care and hospice services on QOL in this population.
Older adults with AML are commonly underrepresented in clinical trials, often due to poor 
performance status, abnormal organ function, or active infection (73, 74). Poor 
representation in clinical trials leads to inadequate evidence and knowledge about responses 
of older patients to medications (2, 75). Major medical breakthroughs in cancer could not 
happen without the generosity of clinical trial participants young and old; therefore, it is 
important for research to include participants of different age, sex, race, and ethnicity (75). 
The lack of recruitment and participation of older adults in clinical trials results in medical 
decisions for older adults being routinely based on data derived from studies of younger 
adults (76). Older adults represent the fastest-growing population nationwide. Therefore, the 
evaluation of new treatment therapies in the older adult population is becoming a major 
issue.
The National Comprehensive Cancer Network, an alliance of leading cancer centers, 
explicitly state clinical trials as the preferred option in patients with untreated AML who are 
aged 60 years and older (73). With longer life expectancy, there is an anticipation that 
treatments will cure and improve QOL (75). Hence, there is a clear need for evidence-based 
interventions for older adults. Evidence-based data ensures that therapies are prescribed to 
the older patient when they may offer a meaningful gain in survival, QOL or both, and 
avoided in situations in which they may not be beneficial (77).
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Conclusions
Caring for the patient holistically is the goal of patient centered care—better management of 
comorbidities and symptoms can lead to improved physical function, ultimately enhancing 
QOL. Currently, AML remains a high mortality disease for adults. Additionally, only a few 
drug studies have incorporated patient reported outcomes (PROs) and even less have tracked 
how these change over time. More clinical trial studies that incorporate PROs from older 
adults with AML are needed to increase our knowledge about ways to improve physical 
function and maximize QOL because maintaining or improving function during treatment is 
critical. Inclusion of patients in clinical trials who are frail, unfit or who have high-risk 
disease should be strongly encouraged by providers. We encourage oncology providers to 
incorporate more comprehensive patient assessments tailored to older adults to assess fitness 
and develop personalized strategies with the interdisciplinary team to improve the care of 
older adults with AML.
Future Directions
As the population grows older, the number of estimated cases for AML will also rise. 
Integration of electronic symptoms into routine electronic records and care remains a high 
priority. Future large scale, multi-centered longitudinal randomized trials are warranted to 
measure the effects of comorbidities on physical and psychological variables of interest, in 
addition to QOL. Studies that test self-management interventions such as exercise are also 
needed to assess its impact on the management of comorbidities, and subsequent 
improvement of symptoms and physical function, thereby improving QOL for older patients 
with AML.
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Table 1
Comprehensive Geriatric Assessment
Domain Tests
Functional Status Activities of Daily Living, Instrumental Activities of Daily Living
Performance Status using ECOG and KPS
Falls—Timed Up and Go
Comorbidity Older American Resources and Services
Cognition Blessed Orientation-Memory Concentration test
Psychologic Hospital Anxiety and Depression Scale
Social Functioning Medical Outcomes Survey (MOS) Social Activity Limitations
Social Support MOS Support Survey: Emotional/Information and Tangible Susbscales
Nutrition Body Mass Index, weight loss, mini-nutritional assessment
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